Adipocytolytic composition and cosmetic method for localized fat reduction
The use of a conjugated compound of cholecalciferol polyethylene glycol succinate (CPGS) addresses the safety concerns of existing injectable lipolytic agents by providing controlled adipocyte lysis for localized fat reduction with minimal side effects.
WO2026115475A1PCT designated stage Publication Date: 2026-06-04VIDA AB
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- VIDA AB
- Filing Date
- 2025-11-27
- Publication Date
- 2026-06-04
AI Technical Summary
Technical Problem
Existing injectable lipolytic agents for fat reduction, such as bile acids and their derivatives, are non-selective and cause significant side effects, including inflammation and toxicity, necessitating a need for compounds that are effective and safe with controlled action.
Method used
A composition comprising a conjugated compound of a cyclic or polycyclic hexyl secondary alcohol and a polyether organic polymer, optionally linked by a hydrocarbon chain, specifically cholecalciferol polyethylene glycol succinate (CPGS), is used for targeted adipocyte lysis with minimal side effects.
Benefits of technology
The composition achieves localized fat reduction with controlled adipocyte lysis, enhancing aesthetic appearance and maintaining body contour while minimizing side effects.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure IB2025062137_04062026_PF_FP_ABST
Abstract
Cosmetic composition comprising a conjugated compound consisting of a hexyl secondary alcohol, a polyether organic polymer and, optionally, a C2-C22 hydrocarbon chain, saturated or unsaturated, cis or trans, linear or branched, with at least two carboxyl groups and its use for removing subcutaneous fat deposits.
Need to check novelty before this filing date? Find Prior Art